LGP Cannatrek starts married life cash-positive, but the honeymoon numbers need careful handling

LGP Cannatrek Group has opened its post-merger era with positive operating cash flow, a healthy cash balance and a clearly defined cost-cutting program. The catch is that the June quarter does not provide a clean picture of the combined business.

The merger between Little Green Pharma and Cannatrek was completed on 1 June 2026. Under the required accounting treatment, the quarterly cash flow statement includes three months of Cannatrek cash flows but only one month from the former Little Green Pharma operations. That means the reported customer receipts and expenditure figures cannot sensibly be compared with earlier quarters, nor treated as a full-quarter run rate for the enlarged group.

The September quarter will therefore be the first proper financial test of the combined operation. Until then, investors are dealing with a financial photograph taken while half the family was still walking into frame.

Operating cash flow moves into positive territory

Net cash from operating activities was $1.85 million, supported by customer receipts of $22.92 million. Product manufacturing and operating costs totalled $7.76 million, staff costs were $5.57 million and administration and corporate costs came to $7.60 million.

The positive operating result is encouraging, especially in a sector where cash burn has often been treated as an occupational hazard. However, the cost base deserves close attention. Administration and corporate spending was almost as high as manufacturing and operating expenditure, while staff and corporate costs together consumed more than $13 million.

Some of that expenditure may reflect the transition to the merged structure, but the report does not break out merger-specific operating costs. Investors will be looking for corporate expenses to moderate as duplicated functions are removed and integration work progresses.

Management has identified $3 million of targeted synergies across manufacturing, cultivation, procurement and corporate functions. That target is meaningful relative to the current cash cost base, although the timing of the savings has not been quantified.

Cash position provides integration breathing room

Cash and cash equivalents finished the period at $20.59 million, up from $17.61 million at the start. The increase included $1.57 million of cash held by the former Little Green Pharma business when the merger became effective, so it was not entirely generated from trading.

The group also had $9.17 million of unused financing facilities, taking total available funding to almost $29.8 million. Financing facilities totalled $15.17 million, of which about $6 million had been drawn.

The company described debt as minimal at $5.9 million at the merger date. Borrowings are spread across property, equipment, inventory and working capital facilities, with interest rates varying according to lender and security arrangements.

This balance sheet gives management some room to integrate the businesses and invest in Europe without immediately returning to shareholders for capital. That matters because the group has begun funding expansion and efficiency initiatives in Denmark, while also building its presence in Germany and the United Kingdom.

One shadow remains the Therapeutic Goods Administration regulatory investigation. Management expects any penalty to be material but says it should remain within the limits of the contingent value share conversion mechanism. That may reduce the direct cash sting, but investors will still want clarity once the regulatory process is resolved.

Australia remains the engine room

Australia accounted for 84 per cent of group sales, with Europe and the United Kingdom contributing the remaining 16 per cent. The geographic weighting has shifted back towards Australia following the addition of Cannatrek, reflecting its strong domestic position.

Flower remained the dominant product category at 79 per cent of sales. Oils contributed 13 per cent, while edibles and vapes each accounted for 4 per cent. Flower is still very much the main course, but Cannatrek’s exposure to oils, edibles and vapes has reduced the combined portfolio’s dependence on it.

Cannatrek-branded products represented 46.9 per cent of sales and Little Green Pharma products contributed 29.6 per cent. Cornerfield accounted for 10.7 per cent and CherryCo 7.6 per cent, with the remaining brands making smaller contributions. Around three-quarters of sales came from the two core brand families, excluding European white-label activity.

Integration execution becomes the key measure

Management is running seven integration workstreams covering operational synergies, the Denmark facility, product optimisation, commercial strategy, technology systems, finance and quality systems.

Early priorities include combining commercial platforms, rationalising product portfolios and consolidating downstream operations. The domestic manufacturing assets and the Danish cultivation and production facility are being presented as complementary rather than duplicated infrastructure.

The strategic logic is straightforward: use Cannatrek’s Australian scale and product breadth alongside Little Green Pharma’s European production footprint and export relationships. The harder task is translating that logic into lower costs, better utilisation and sustainable cash generation.

The June quarter offers an encouraging starting point, but not yet a reliable trend. The next quarterly result should reveal whether positive operating cash flow survives a full three months of combined trading and whether the promised synergies are beginning to appear where they matter most - in the bank account.